Growth hormone replacement therapy    (DrugBank: Growth hormone)

1 disease
IDDisease name (Link within this page)Number of trials
78Hypopituitarism16

78. Hypopituitarism    [ 462 clinical trials,   346 drugs,   (DrugBank: 45 drugs),   41 drug target genes,   80 drug target pathways]
Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
16 / 462 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04121780
(ClinicalTrials.gov)
October 8, 201925/9/2019Growth Hormone Replacement Therapy for Retried Professional Football PlayersInterventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone DeficiencyTBI (Traumatic Brain Injury);Concussion, Brain;Sport Injury;Anterior Pituitary Hyposecretion Syndrome;Hypopituitarism;Growth Hormone DeficiencyBiological: Growth Hormone;Other: PlaceboCenter for Neurological StudiesNovo Nordisk A/SRecruiting18 Years76 YearsMale42Phase 2United States
2NCT02243852
(ClinicalTrials.gov)
September 201416/9/2014Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)Evaluation of the Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) Concentration in Patients With Growth Hormone Deficiency (GHD)Growth Hormone DeficiencyDrug: Growth Hormone Replacement TherapyUniversity of LiverpoolPfizerRecruiting18 Years80 YearsBoth48N/AUnited Kingdom
3EUCTR2012-005066-36-NL
(EUCTR)
15/05/201323/01/2013To investigate the effect of different doses of Growth Hormone treatment on the risk of developing cardiovascular diseases in patients with growth hormone deficiencyEffect of Growth Hormone replacement therapy on cardiovascular risk factors in adult patients with severe growth hormone deficiency: association with IGF-I concentration - GH and cardiovascular risk factors Growth hormone deficiency;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: Genotropin
Trade Name: Norditropin
Trade Name: Humatrope
Trade Name: Zomacton
VU University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
4NCT01877512
(ClinicalTrials.gov)
May 201311/6/2013GH and Cardiovascular Risk FactorsEffect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I ConcentrationGrowth Hormone Deficiency;Cardiovascular Diseases;Metabolic Syndrome;Cognition;Physical ActivityDrug: Change in daily dosage of Growth HormoneVU University Medical CenterNULLCompleted20 Years65 YearsBoth32Phase 4Netherlands
5NCT00630487
(ClinicalTrials.gov)
May 200828/2/2008Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone DeficiencyProspective, Randomized, Double Blind Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Adult Patients With Isolated Growth Hormone Deficiency (PRO ISO-GHD Study)Growth Hormone DeficiencyDrug: Placebo;Drug: SomatropinPfizerNULLTerminated18 Years65 YearsAll9Phase 3Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00555009
(ClinicalTrials.gov)
March 200824/10/2007Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain InjuryPlacebo Controlled Trial on the Efficacy of Growth Hormone Replacement Therapy in Patients With Growth Hormone Deficiency After Traumatic Brain Injury.Brain Injuries;Growth Hormone DeficiencyDrug: Genotropin;Drug: PlaceboPfizerNULLTerminated18 Years55 YearsAll10Phase 4France;Italy;Netherlands;Spain;Sweden;United Kingdom
7EUCTR2007-003586-41-FR
(EUCTR)
13/02/200814/11/2007Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/APlacebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A Growth hormone deficiency after traumatic brain injury
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Trade Name: Genotropin/GENOTONORM®
Product Name: Genotropin/GENOTONORM®
Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UKNULLNot RecruitingFemale: yes
Male: yes
120United Kingdom;Netherlands;France;Spain;Italy;Sweden
8EUCTR2007-000790-36-DE
(EUCTR)
08/01/200812/12/2007Prospective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study) - PRO ISO-GHD StudyProspective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study) - PRO ISO-GHD Study Isolated Adult Growth Hormone Deficiency
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Trade Name: Genotropin 5 mg/ml
INN or Proposed INN: Somatropin
Trade Name: Genotropin 5 mg/ml
INN or Proposed INN: Somatropin
Pfizer Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
50Germany
9EUCTR2007-003586-41-NL
(EUCTR)
17/12/200709/08/2007Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/APlacebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A Growth hormone deficiency after traumatic brain injury
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Trade Name: Genotropin
Product Name: Genotropin
Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UKNULLNot RecruitingFemale: yes
Male: yes
120United Kingdom;Netherlands;France;Spain;Italy;Sweden
10EUCTR2007-003586-41-ES
(EUCTR)
26/11/200720/11/2007Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injuryEnsayo controlado con placebo sobre la eficacia del tratamiento de reposición de hormona de crecimiento en pacientes con déficit de hormona de crecimiento después de un traumatismo cerebral. - N/APlacebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injuryEnsayo controlado con placebo sobre la eficacia del tratamiento de reposición de hormona de crecimiento en pacientes con déficit de hormona de crecimiento después de un traumatismo cerebral. - N/A Tratamiento del déficit de hormona de crecimiento en adultos después de un traumatismo cerebral.
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Trade Name: Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin)
Product Name: Genotonorm Kabipen 5.3 mg polvo y disolvente para sol. inyectable (Marca internacional Genotropin)
INN or Proposed INN: Somatropina
Pfizer, S.ANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120United Kingdom;Netherlands;France;Spain;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2007-003586-41-SE
(EUCTR)
21/11/200712/09/2007Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/APlacebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A Growth hormone deficiency after traumatic brain injury
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Trade Name: Genotropin
Product Name: Genotropin
Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UKNULLNot RecruitingFemale: yes
Male: yes
120United Kingdom;Netherlands;France;Spain;Italy;Sweden
12EUCTR2007-003586-41-GB
(EUCTR)
15/11/200711/10/2007Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/APlacebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A Growth hormone deficiency after traumatic brain injury
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Trade Name: Genotropin
Product Name: Genotropin
Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UKNULLNot RecruitingFemale: yes
Male: yes
120United Kingdom;Netherlands;France;Spain;Italy;Sweden
13NCT00491582
(ClinicalTrials.gov)
July 200725/6/2007The Effects of Growth Hormone (GH) on Lipid DepotsThe Effect of Growth Hormone (GH) on Intramyocellular Lipids (IMCL), Intrahepatocellular Lipids (IHCL) and Visceral Fat Mass in Relation to Insulin ResistanceGrowth Hormone DeficiencyDrug: Growth hormone replacement therapy in growth hormone deficient patients only.University Hospital Inselspital, BerneSwiss National Science FoundationCompleted18 Years80 YearsBoth34N/ASwitzerland
14NCT00432263
(ClinicalTrials.gov)
April 20075/2/2007Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain InjuryBrain InjuriesDrug: Genotropin (PN-180,307) SomatropinPfizerNULLWithdrawn18 Years55 YearsBoth0Phase 4NULL
15NCT01576861
(ClinicalTrials.gov)
January 200719/3/2012Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart FailureGrowth Hormone Deficiency;Chronic Heart FailureDrug: SomatotropinFederico II UniversityNULLCompleted18 Years80 YearsBoth28Phase 2Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT01698944
(ClinicalTrials.gov)
May 16, 20011/10/2012Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone DeficiencyCardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone DeficiencyGrowth Hormone Disorder;Adult Growth Hormone DeficiencyDrug: somatropinNovo Nordisk A/SNULLTerminated12 Years25 YearsAll7Phase 4Greece